tag:blogger.com,1999:blog-8550428.post7953388913574142308..comments2024-03-27T01:34:23.434-04:00Comments on Pharma Marketing Blog: Uh, Oh! Will FDA Cite this "One-Click Rule" Twitter Post by AZ as Violative?Vladhttp://www.blogger.com/profile/04114063498108633047noreply@blogger.comBlogger5125tag:blogger.com,1999:blog-8550428.post-9691852476805408262009-06-01T14:59:07.227-04:002009-06-01T14:59:07.227-04:00I say no. I think it's okay. They aren't promoti...I say no. I think it's okay. They aren't promoting the benefits, but pointing to a study that evaluates them. I think this is a fine line, but clearly on the right side.<br /><br />In the analysis my team did on this issue we took a pretty conservative line on what's okay and what isn't. I think this falls fairly safe -- risky -- but acceptable.<br /><br />I linked my name to the whitepaper for the interested.CarlenLeahttp://www.rtcrm.com/whitepapersnoreply@blogger.comtag:blogger.com,1999:blog-8550428.post-70567525599049591962009-05-29T14:46:41.619-04:002009-05-29T14:46:41.619-04:00Jonathan,
Thanks for pointing this out. Your pres...Jonathan,<br /><br />Thanks for pointing this out. Your presentation was where I found out about this, but I did not want to use your name in case what I said came back to bite you in the behind! But since you volunteered...PharmaGuyhttps://www.blogger.com/profile/10211557578124130640noreply@blogger.comtag:blogger.com,1999:blog-8550428.post-6893492517479456452009-05-29T14:12:36.171-04:002009-05-29T14:12:36.171-04:00No question these are violative. I pointed these o...No question these are violative. I pointed these out in a presentation I did about a month ago called Pharma and Healthcare Social Media Principles. I first noted that AZ was being "conservative" using Twitter only to really post press release items. I then noted these same two tweets and commented that it was ironic that in their goal to be conservative, they managed to violate rule one of DDMAC. No drug name and indication without fair balance.<br /><br />Here's a link to the presentation: http://bit.ly/5G1UF<br /><br />Check out slides 21-23.Jonathan Richmanhttp://www.doseofdigital.comnoreply@blogger.comtag:blogger.com,1999:blog-8550428.post-11686593659253860752009-05-28T09:51:18.547-04:002009-05-28T09:51:18.547-04:00Thanks for your comments. Some good points about w...Thanks for your comments. Some good points about which it would be nice to have some FDA guidance.PharmaGuyhttps://www.blogger.com/profile/10211557578124130640noreply@blogger.comtag:blogger.com,1999:blog-8550428.post-5625573988994838462009-05-28T09:42:54.580-04:002009-05-28T09:42:54.580-04:00Might be a bit of a strawman you have taken this t...Might be a bit of a strawman you have taken this too here. The tweets/release links pointed out would be considered scientific exchange since they report study results... SciExhas always been viewed differently than product promotion/advertising. Now the FDA also does not clearly define what is considered scientific exchange versus promotion but I think thats a different bag of worms.<br /><br />Now lets say for some reason the company continually posted similar tweets (once a week or something) after the initial information was released, that might become an issue of promotion in the FDA's mind.Anonymousnoreply@blogger.com